Arturo J Rios-Diaz1, Ryan Lamm2, David Metcalfe3, Courtney L Devin2, Michael J Pucci2, Francesco Palazzo2. 1. Department of Surgery, Thomas Jefferson University Hospital, 1015 Walnut Street, Philadelphia, PA, 19107, USA. Arturo.RiosDiaz@jefferson.edu. 2. Department of Surgery, Thomas Jefferson University Hospital, 1015 Walnut Street, Philadelphia, PA, 19107, USA. 3. Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Department of Orthopedics, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: National and international guidelines support early cholecystectomy after mild gallstone pancreatitis but a recent nationwide study suggested these recommendations are not universally followed. Our study sought to quantify the national utilization of same hospitalization cholecystectomy versus non-operative management (NOM) and its association with pancreatitis recurrence, readmissions, and costs after mild gallstone pancreatitis (GP). METHODS: Adult patients admitted with mild GP were identified from the Nationwide Readmission Database 2010-2015. Primary outcomes included the rate of cholecystectomy during the index admission as well as pancreatitis recurrence and readmission at 30 and 180 days (30d, 180d) comparing NOM to same hospitalization cholecystectomy. Mortality upon readmission, total length of stay (LOS), and total costs (combined index-readmission hospital costs) were also explored. Cox proportional hazards regression and generalized linear models controlled for patient/hospital confounders. RESULTS: Among the 65,067 patients identified, 30% underwent cholecystectomy. The NOM cohort was older (58 vs. 50 years), had more comorbidities (Charlson index > 2, 23.5% vs. 11.5%), fewer female patients (56.7% vs. 67%) and less discharge-to-home (84.9% vs. 94.4%) (all p < 0.001). NOM was associated with increase in recurrence and unplanned readmissions at 30d [Hazard Ratio 3.53 (95% CI 2.92-4.27), 2.41 (2.11-2.74), respectively], and 180d [4.27 (3.65-4.98), 2.78 (2.54-3.04), respectively], as well as increased mortality during 180d readmission 1.88 (1.06-3.35). This approach was also associated with significant increase in LOS [predicted mean difference 2.79 days (95% CI 2.46-3.12)] and total costs [$2507.89 ($1714.4-$3301.4)]. CONCLUSIONS: In the USA, most patients presenting with mild GP do not undergo same hospitalization cholecystectomy. This strategy results in higher recurrent pancreatitis, mortality during readmission, and an additional $4.85 M/year in hospital costs nationwide. These data support same hospitalization cholecystectomy as the gold standard for mild GP.
BACKGROUND: National and international guidelines support early cholecystectomy after mild gallstone pancreatitis but a recent nationwide study suggested these recommendations are not universally followed. Our study sought to quantify the national utilization of same hospitalization cholecystectomy versus non-operative management (NOM) and its association with pancreatitis recurrence, readmissions, and costs after mild gallstone pancreatitis (GP). METHODS: Adult patients admitted with mild GP were identified from the Nationwide Readmission Database 2010-2015. Primary outcomes included the rate of cholecystectomy during the index admission as well as pancreatitis recurrence and readmission at 30 and 180 days (30d, 180d) comparing NOM to same hospitalization cholecystectomy. Mortality upon readmission, total length of stay (LOS), and total costs (combined index-readmission hospital costs) were also explored. Cox proportional hazards regression and generalized linear models controlled for patient/hospital confounders. RESULTS: Among the 65,067 patients identified, 30% underwent cholecystectomy. The NOM cohort was older (58 vs. 50 years), had more comorbidities (Charlson index > 2, 23.5% vs. 11.5%), fewer female patients (56.7% vs. 67%) and less discharge-to-home (84.9% vs. 94.4%) (all p < 0.001). NOM was associated with increase in recurrence and unplanned readmissions at 30d [Hazard Ratio 3.53 (95% CI 2.92-4.27), 2.41 (2.11-2.74), respectively], and 180d [4.27 (3.65-4.98), 2.78 (2.54-3.04), respectively], as well as increased mortality during 180d readmission 1.88 (1.06-3.35). This approach was also associated with significant increase in LOS [predicted mean difference 2.79 days (95% CI 2.46-3.12)] and total costs [$2507.89 ($1714.4-$3301.4)]. CONCLUSIONS: In the USA, most patients presenting with mild GP do not undergo same hospitalization cholecystectomy. This strategy results in higher recurrent pancreatitis, mortality during readmission, and an additional $4.85 M/year in hospital costs nationwide. These data support same hospitalization cholecystectomy as the gold standard for mild GP.
Authors: David W da Costa; Stefan A Bouwense; Nicolien J Schepers; Marc G Besselink; Hjalmar C van Santvoort; Sandra van Brunschot; Olaf J Bakker; Thomas L Bollen; Cornelis H Dejong; Harry van Goor; Marja A Boermeester; Marco J Bruno; Casper H van Eijck; Robin Timmer; Bas L Weusten; Esther C Consten; Menno A Brink; B W Marcel Spanier; Ernst Jan Spillenaar Bilgen; Vincent B Nieuwenhuijs; H Sijbrand Hofker; Camiel Rosman; Annet M Voorburg; Koop Bosscha; Peter van Duijvendijk; Jos J Gerritsen; Joos Heisterkamp; Ignace H de Hingh; Ben J Witteman; Philip M Kruyt; Joris J Scheepers; I Quintus Molenaar; Alexander F Schaapherder; Eric R Manusama; Laurens A van der Waaij; Jacco van Unen; Marcel G Dijkgraaf; Bert van Ramshorst; Hein G Gooszen; Djamila Boerma Journal: Lancet Date: 2015-09-26 Impact factor: 79.321
Authors: Scott Kizy; Cyrus Jahansouz; Michael C Downey; Nathanael Hevelone; Sayeed Ikramuddin; Daniel Leslie Journal: Obes Surg Date: 2017-11 Impact factor: 4.129
Authors: Mohammad Bilal; Kevin T Kline; Judy A Trieu; Hamzeh Saraireh; Madhav Desai; Sreeram Parupudi; Marwan S Abougergi Journal: Pancreatology Date: 2019-04-22 Impact factor: 3.996
Authors: Waldemar Uhl; Andrew Warshaw; Clement Imrie; Claudio Bassi; Colin J McKay; Paul G Lankisch; Ross Carter; Eugene Di Magno; Peter A Banks; David C Whitcomb; Christos Dervenis; Charles D Ulrich; Kat Satake; Paula Ghaneh; Werner Hartwig; Jens Werner; Gerry McEntee; John P Neoptolemos; Markus W Büchler Journal: Pancreatology Date: 2002 Impact factor: 3.996
Authors: Anne F Peery; Evan S Dellon; Jennifer Lund; Seth D Crockett; Christopher E McGowan; William J Bulsiewicz; Lisa M Gangarosa; Michelle T Thiny; Karyn Stizenberg; Douglas R Morgan; Yehuda Ringel; Hannah P Kim; Marco Dacosta DiBonaventura; Charlotte F Carroll; Jeffery K Allen; Suzanne F Cook; Robert S Sandler; Michael D Kappelman; Nicholas J Shaheen Journal: Gastroenterology Date: 2012-08-08 Impact factor: 22.682
Authors: Peter J Fagenholz; Carlos Fernández-del Castillo; N Stuart Harris; Andrea J Pelletier; Carlos A Camargo Journal: Pancreas Date: 2007-11 Impact factor: 3.327